SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 30 of 94
Word Count: 1425
Character Count: 9128

Document Content:

or De Novo classification. While BDD allows for increased interaction with FDA reviewers and prioritized submission review, it does not guarantee product approval, faster approval, or commercial success. The Revivent System remains subject to extensive regulatory requirements, including but not limited to premarket approval, manufacturing quality systems, labeling, and post-market surveillance. Medical devices may only be marketed for uses approved by the FDA, and we must comply with the FDA’s QSR, covering manufacturing, testing, labeling, and documentation processes. Our manufacturing facilities and those of our suppliers are subject to periodic FDA inspections, which may be unannounced. Any failure to comply with applicable regulations could delay approval, limit commercialization, or lead to enforcement actions that could materially impact our business. Risks Related to Our Securities and this Offering active trading market for our common stock currently exists, and an active trading market may not develop or be sustained following this offering.

Prior
to this offering, there has not been an active trading market for our common stock. If an active trading market for our common stock
does not develop following this offering, you may not be able to sell your shares quickly or at the market price. Our ability to raise
capital to continue to fund operations by selling shares of our common stock and our ability to acquire other companies or technologies
by using shares of our common stock as consideration may also be impaired. The initial public offering price of our common stock will
be determined by negotiations between us and the underwriters and may not be indicative of the market prices of our common stock that
will prevail in the trading market.

The
trading price of our common stock may be volatile, and you could lose all or part of your investment.

Prior
to this offering, there has been no public market for shares of our common stock. The initial public offering price of our common stock
will be determined through negotiations between us and the underwriters. This price does not necessarily reflect the price at which investors
in the market will be willing to buy and sell shares of our common stock following this offering. In addition, the trading price of our
common stock following this offering is likely to be volatile and could be subject to fluctuations in response to various factors, some
of which are beyond our control. These fluctuations could cause you to lose all or part of your investment in our common stock as you
might be unable to sell your shares at or above the price you paid in this offering. Factors that could cause fluctuations in the trading
price of our common stock include the following:

●	price
and volume fluctuations in the overall stock market from time to time;

●	volatility
in the trading prices and trading volumes of transportation stocks;

●	changes
in operating performance and stock market valuations of other transportation companies generally, or those in our industry in particular;

●	sales
of shares of our common stock by us or our stockholders;

●	failure
of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow our company,
or our failure to meet these estimates or the expectations of investors;

●	the
financial projections we may provide to the public, any changes in those projections, or our failure to meet those projections;

●	announcements
by us or our competitors of new product candidates, features, or services;

●	the
public’s reaction to our press releases, other public announcements and filings with the SEC;

●	rumors
and market speculation involving us or other companies in our industry;

●	actual
or anticipated changes in our results of operations or fluctuations in our results of operations;

●	actual
or anticipated developments in our business, our competitors’ businesses or the competitive landscape generally;

●	litigation
involving us, our industry, or both, or investigations by regulators into our operations or those of our competitors;

●	developments
or disputes concerning our intellectual property or other proprietary rights;

●	announced
or completed acquisitions of businesses, product candidates, services or technologies by us or our competitors;

●	new
laws or regulations or new interpretations of existing laws or regulations applicable to our business;

●	changes
in accounting standards, policies, guidelines, interpretations or principles;

●	any
significant change in our management; and

●	general
economic conditions and slow or negative growth of our markets.

recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of listed companies. Broad market and industry factors may significantly affect the market price of our
common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for
our common stock shortly following this offering. If the market price of shares of our common stock after this offering does not ever
exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment.

addition, in the past, following periods of volatility in the overall market and in the market price of a particular company’s
securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against
us, could result in substantial costs and a diversion of our management’s attention and resources.

Certain
recent initial public offerings of companies with public floats comparable to our anticipated public float have experienced extreme volatility
that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may
make it difficult for prospective investors to assess the value of our common stock.

addition to the risks addressed above in “Risks Relating to Our Securities and this Offering — The trading price of our
common stock may be volatile, and you could lose all or part of your investment,” our common stock may be subject to extreme
volatility that is seemingly unrelated to the underlying performance of our business. Recently, companies with comparable public floats
and initial public offering sizes have experienced instances of extreme stock price run-ups followed by rapid price declines, and such
stock price volatility was seemingly unrelated to the respective company’s underlying performance. Although the specific cause
of such volatility is unclear, our anticipated public float may amplify the impact the actions taken by a few stockholders have on the
price of our common stock, which may cause the price of our common stock to deviate, potentially significantly, from a price that better
reflects the underlying performance of our business. Should our common stock experience run-ups and declines that are seemingly unrelated
to our actual or expected operating performance and financial condition or prospects, prospective investors may have difficulty assessing
the rapidly changing value of our common stock. In addition, investors of shares of our common stock may experience losses, which may
be material, if the price of our common stock declines after this offering or if such investors purchase shares of our common stock prior
to any price decline.

securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.

The
trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities
or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. If we obtain securities
or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable
research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to
publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.

Future
sales of our common stock or securities convertible, exchangeable or exercisable into our common stock may depress our stock price.

Sales
of a substantial number of shares of our common stock or securities convertible, exchangeable or exercisable into our common stock
in the public market after the completion of this offering, or the perception that these sales could occur, could adversely affect the
market price of our common stock and could materially impair our ability to raise capital through equity offerings in the future.